Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Shock

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    318 result(s) found for: Shock. Displaying page 2 of 16.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2016-000707-81 Sponsor Protocol Number: VIPER-SEPSIS Start Date*: 2016-04-26
    Sponsor Name:Section for Transfusion Medicine, Capitol Region Blood Bank
    Full Title: Vasculopathic Injury and Plasma as Endothelial Rescue in septic shock (SEPSIS) trial
    Medical condition: Patients with septic shock admitted to the intensive care unit
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10040070 Septic shock PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002824-17 Sponsor Protocol Number: ACCOST-HH Start Date*: 2019-02-28
    Sponsor Name:University Medical Centre Hamburg-Eppendorf
    Full Title: Placebo-controlled, double-blind, randomized trial to assess the efficacy and safety of Adrecizumab in subjects with cardiogenic shock
    Medical condition: Cardiogenic shock
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007625 Cardiogenic shock PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-003846-10 Sponsor Protocol Number: MJIP1.0 Start Date*: 2024-05-02
    Sponsor Name:Fakultní nemocnice Plzeň
    Full Title: A pilot study comparing the haemodynamic effects and safety of an intravenous fluid bolus of 0.5M sodium lactate against 3% saline in patients with septic shock
    Medical condition: Septic shock fluid treatment
    Disease: Version SOC Term Classification Code Term Level
    26.0 10021881 - Infections and infestations 10040580 Shock septic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-001131-31 Sponsor Protocol Number: COMBAT-SHINE Start Date*: 2019-06-25
    Sponsor Name:Section for transfusion Medicines, Capital Region Blood Bank, Copenhagen University Hospital
    Full Title: “Efficacy and safety of 72-hour infusion of Prostacyclin (1 ng/kg/min) in patients with septic shock induced endotheliopathy – a multicentre randomized, placebo-controlled, blinded, investigator-in...
    Medical condition: Shock-induced endotheliopathy in patients with septic shock
    Disease: Version SOC Term Classification Code Term Level
    23.1 10021881 - Infections and infestations 10040070 Septic shock PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-002440-41 Sponsor Protocol Number: CO-ILEPSS Start Date*: 2014-08-14
    Sponsor Name:Rigshospitalet, Capital Region Bloodbank 2034, Section for Transfusion Medicine
    Full Title: Safety and efficacy of iloprost and eptifibatide co-administration compared to standard therapy in patients with septic shock – a randomized, controlled, double-blind investigator-initiated trial
    Medical condition: Septic shock
    Disease: Version SOC Term Classification Code Term Level
    17.0 10021881 - Infections and infestations 10040070 Septic shock PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2010-023129-39 Sponsor Protocol Number: MP4OX-10-TRA-205 Start Date*: 2011-03-22
    Sponsor Name:Sangart, Inc.
    Full Title: Estudio multicéntrico, aleatorizado, en doble ciego y controlado, para evaluar la seguridad y la eficacia del tratamiento con MP4OX, añadido al tratamiento habitual, en pacientes con traumatismo se...
    Medical condition: Pacientes con traumatismo severo y acidosis láctica por shock hemorrágico.//Severely injured trauma patients with lactic acidosis due to hemorrhagic shock.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10050841 Hemorrhagic shock LLT
    12.1 10023676 Lactic acidosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) AT (Completed) DE (Completed) GB (Completed) NO (Completed) IT (Ongoing) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-005687-27 Sponsor Protocol Number: TAK-242_301 Start Date*: 2008-08-06
    Sponsor Name:Takeda Global Research & Development Centre (Europe), Ltd. [...]
    1. Takeda Global Research & Development Centre (Europe), Ltd.
    2. Takeda Global Research & Development Centre (Europe), Ltd.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of TAK-242 Versus Placebo in Subjects With Sepsis Induced Cardiovascular and Respiratory Failure
    Medical condition: Septic shock and respiratory failure.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10040070 Septic shock PT
    9.1 10038695 Respiratory failure PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) FI (Completed) CZ (Prematurely Ended) HU (Prematurely Ended) FR (Completed) AT (Prematurely Ended) NL (Prematurely Ended) SE (Prematurely Ended) DE (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-004319-29 Sponsor Protocol Number: P170914J Start Date*: 2021-10-04
    Sponsor Name:ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS (AP-HP)
    Full Title: " LEVOSIMENDAN to facilitate weaning from ECMO in severe cardiogenic shock patients
    Medical condition: Adult patients with acute cardiogenic shock refractory to conventional therapy placed on VA-ECMO support and for whom withdrawal from ECMO is possible.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007625 Cardiogenic shock PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-001949-20 Sponsor Protocol Number: 1.0 Start Date*: 2023-01-09
    Sponsor Name:ALBIMMUNE S.L.
    Full Title: Human albumin treatment in adult septic shock. A phase 2, multicenter, randomized, controlled study evaluating the immune response and organ failure.
    Medical condition: Septic Shock
    Disease: Version SOC Term Classification Code Term Level
    23.1 10021881 - Infections and infestations 10040070 Septic shock PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-005032-14 Sponsor Protocol Number: MOT-C-201 Start Date*: 2017-04-27
    Sponsor Name:INOTREM S.A.
    Full Title: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 3 Doses of MOTREM in Patients with Septic Shock. A Randomised, Double-blind, Two-stage, Placebo Controlled Study.
    Medical condition: Septic shock
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10040070 Septic shock PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-002708-17 Sponsor Protocol Number: LOCAL/2016/CR-01 Start Date*: 2016-11-25
    Sponsor Name:CHU de NIMES
    Full Title: Pharmacokinetic study on echinocandins for patients with septic shock following secondary peritonitis
    Medical condition: septic shock following secondary peritonitis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10040580 Shock septic LLT
    19.0 100000004862 10061135 Spontaneous bacterial peritonitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004350-25 Sponsor Protocol Number: 06-HE06-01 Start Date*: 2007-02-06
    Sponsor Name:Fresenius Kabi Deutschland GmbH
    Full Title: Crystalloids or colloids in patients with severe sepsis: effects on hemodynamics and tolerability of enteral nutrition
    Medical condition: Severe sepsis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10040070 Septic shock LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-006445-41 Sponsor Protocol Number: CTSSTS1010207V2 Start Date*: 2012-01-28
    Sponsor Name:HEALTH RICERCAE SVILUPPO SRL
    Full Title: The irreversibility of hemorrhagic shock treatment with anti-opiod neuropeptide
    Medical condition: Mortality of hemorrhagic shock grade 2 and 3 is from 50 to '80% in the first 24 hours, and morbidity and mortality betrayed is to 7 to 8 days of' 90% for Acute Respiratory Distress Syndrome and / o...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10047065 - Vascular disorders 10049771 Shock haemorrhagic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-003238-35 Sponsor Protocol Number: 4_141221 Start Date*: 2021-09-15
    Sponsor Name:Oslo University Hospital
    Full Title: Effects of supplemental oxygen on systemic and cerebral hemodynamics in experimental hypovolemia: A randomized, phase IV, crossover study to study the effect of supplemental oxygen vs. room air on ...
    Medical condition: Hypovolemia is the condition under investigation. Hypovolemia is induced by the "lower body negative pressure" (LBNP)-model.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10049771 Shock haemorrhagic PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: View results
    EudraCT Number: 2009-012639-13 Sponsor Protocol Number: 28180 Start Date*: 2009-06-29
    Sponsor Name:Meander Medical Centre
    Full Title: Combined intracutaneous and intraperitoneal anaesthesia for postoperative pain reduction after laparoscopic cholecystectomy
    Medical condition: Symptomatic gallstone disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018109 Generalized convulsive epilepsy LLT
    9.1 10007647 Cardiovascular collapse LLT
    9.1 10002199 Anaphylactic shock LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-004485-40 Sponsor Protocol Number: P070128 Start Date*: 2008-01-30
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Etude prospective, multicentrique contrôlée vs placebo, randomisée, en double insu comparant la protéine C activée, les faibles doses de corticoïdes et leur association dans le traitement du choc s...
    Medical condition: Choc septique
    Disease: Version SOC Term Classification Code Term Level
    8.1 10040580 Choc septique PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-017081-23 Sponsor Protocol Number: CPRC2009 - OPTIMA CC Start Date*: 2010-03-22
    Sponsor Name:Centre Hospitalier Universitaire de Nancy
    Full Title: Optimisation du traitement du choc cardiogénique. Etude pilote physiopathologique ouverte multicentrique comparant l’efficacité et la tolérance de l’adrénaline et la noradrénaline (Optima CC)
    Medical condition: choc cardiogénique
    Disease: Version SOC Term Classification Code Term Level
    12.1 10007625 Cardiogenic shock LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-005159-18 Sponsor Protocol Number: CRO2047 Start Date*: 2013-08-28
    Sponsor Name:Imperial College, London
    Full Title: An efficacy and mechanism evaluation study of Levosimendan for the Prevention of Acute oRgan Dysfunction in Sepsis (LeoPARDS)
    Medical condition: Septic shock.
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004867 10028237 Multiple organ failure LLT
    16.0 10021881 - Infections and infestations 10040070 Septic shock PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-001862-12 Sponsor Protocol Number: s63213 Start Date*: 2021-03-23
    Sponsor Name:University Hospitals Leuven, Clinical Trial Centre
    Full Title: Early administration of Vitamin C in patients with sepsis or septic shock in emergency departments: a multicentre, double blinded, randomized controlled trial: the C-EASIE trial.
    Medical condition: We will investigate the potential benefit of early administration of high doses of Vitamin C in addition to standard care in patients with sepsis or septic shock.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10040047 Sepsis PT
    23.1 10021881 - Infections and infestations 10040070 Septic shock PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-005756-37 Sponsor Protocol Number: CONTENTSS Start Date*: 2021-11-02
    Sponsor Name:Fundación Pública Andaluza para la Gestión de la
    Full Title: Double blind randomized clinical trial comparing noradrenaline plus placebo versus noradrenaline plus terlipressin in septic shock
    Medical condition: Patients with septic shock who remain without reaching the hemodynamic goal of TAM> 65 mmHg, despite volume replacement and administration of noradrenaline at doses equal to or greater than 0.2 μg ...
    Disease: Version SOC Term Classification Code Term Level
    23.1 10021881 - Infections and infestations 10040070 Septic shock PT
    20.0 10021881 - Infections and infestations 10040089 Septicemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 21:05:04 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA